News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cleveland Biolabs Inc. (CBLI) Announces Publication of Studies Identifying Biomarkers of CBLB502's Efficacy as a Radiation Countermeasure


8/1/2012 9:28:52 AM

BUFFALO, N.Y., Aug. 1, 2012 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) today announced the online publication of studies identifying biomarkers of CBLB502's efficacy as a radiation countermeasure in the Journal of Pharmacology and Experimental Therapeutics, a leading peer-reviewed research journal in the field of pharmacology. The reported studies were conducted by scientists of Cleveland BioLabs in collaboration with researchers at the Armed Forces Radiobiology Research Institute and the F. Edward H├ębert School of Medicine at the Uniformed Services University of the Health Sciences, and Roswell Park Cancer Institute.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES